Commercial Supply Alogliptin Benzoate (CAS: 850649-62-6) Related Intermediates:
6-Chloro-3-methyluracil CAS: 4318-56-3
2-Cyanobenzyl Bromide CAS: 22115-41-9
(R)-(-)-3-Aminopiperidine Dihydrochloride CAS: 334618-23-4
2-[(6-Chloro-3,4-dihydro-3-Methyl-2,4-dioxo-1(2h)-pyriMidinyl)Methyl]benzonitrile CAS: 865758-96-9
| Chemical Name |
2-Cyanobenzyl Bromide |
| Synonyms |
2-(Bromomethyl)benzonitrile; α-Bromo-o-tolunitrile |
| CAS Number |
22115-41-9 |
| CAT Number |
RF-PI142 |
| Stock Status |
In Stock, Production Scale Up to Tons |
| Molecular Formula |
C8H6BrN |
| Molecular Weight |
196.04 |
| Melting Point |
72.0~74.0 ℃ |
| Boiling Point |
111 ℃/1.5 mmHg |
| Solubility in Water |
Slightly Soluble |
| Solubility (Soluble in) |
Methanol |
| Brand |
Ruifu Chemical |
| Item |
Specifications |
| Appearance |
White or Off-White to Pale Yellow Powder |
| Purity / Analysis Method |
≥99.0% (HPLC) |
| Moisture (K.F) |
≤0.50% |
| Max Single Impurity |
≤0.50% |
| Residue on Ignition |
≤0.50% |
| Test Standard |
Enterprise Standard |
| Usage |
Alogliptin Benzoate (CAS: 850649-62-6) Intermediate |
Package: Bottle, Aluminum foil bag, Cardboard drum, 25kg/Drum, or according to customer's requirement.
Storage Condition: Store in sealed containers at cool and dry place; Protect from light, moisture and pest infestation.
Shanghai Ruifu Chemical Co., Ltd. is the leading manufacturer and supplier of 2-Cyanobenzyl Bromide (CAS: 22115-41-9) with high quality, widely used in organic synthesis, synthesis of pharmaceutical intermediates and active pharmaceutical ingredient (API) synthesis.
2-Cyanobenzyl Bromide (CAS: 22115-41-9) is used in the synthesis of Alogliptin Benzoate (CAS: 850649-62-6).
Alogliptin Benzoate (CAS: 850649-62-6) is a type-2 diabetes medication, and it is a type of serine protease dipeptidyl peptidase IV (DPP-4) inhibitor. Alogliptin, used alone or in combination with other blood sugar-lowering medication, is usually well-tolerated in type-2 diabetes patients. This medication has a low risk of hypoglycemia, with Alogliptin treatment groups ≤8.3% and placebo groups ≤10.5%, and shows no difference between young and elderly patients. In addition to effectively lowering blood sugar, this medicine also lowers the risks of hypoglycemia and weight increase, overcoming great obstacles in patient treatment and providing new hope for diabetes treatment.